A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

2.

Bazinet

A

,

Darbaniyan

F

,

Jabbour

E

, et al.

Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study

.

Lancet Haematol

.

2022

;

9

(

10

):

e756

-

e765

.

3.

Pratz

KW

,

Jonas

BA

,

Pullarkat

V

, et al.

Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia

.

Am J Hematol

.

2024

;

99

(

4

):

615

-

624

.

4.

Saunthararajah

Y

,

Sekeres

M

,

Advani

A

, et al.

Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes

.

J Clin Invest

.

2015

;

125

(

3

):

1043

-

1055

.

5.

Awada

H

,

Mahfouz

RZ

,

Kishtagari

A

, et al.

Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies

.

Br J Haematol

.

2020

;

188

(

6

):

924

-

929

.

6.

Jones

CL

,

Stevens

BM

,

Pollyea

DA

, et al.

Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells

.

Cell Stem Cell

.

2020

;

27

(

5

):

748

-

764.e4

.

7.

Abaza

Y

,

Winer

ES

,

Murthy

GSG

, et al.

Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers

.

Am J Hematol

.

2024

;

99

(

4

):

606

-

614

.

8.

Short

NJ

,

Daver

N

,

Dinardo

CD

, et al.

Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML

.

J Clin Oncol

.

2024

;

42

(

13

):

1499

-

1508

.

9.

Gilead statement on discontinuation of phase 3 ENHANCE-3 study in AML

. News release. Gilead Sciences, Inc.

7 February 2024

Accessed 9 February 2024. https://www.gilead.com/company/company-statements/2024/gilead-statement-on-discontinuation-of-phase-3-enhance-3-study-in-aml.

10.

Morsia

E

,

McCullough

K

,

Joshi

M

, et al.

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients

.

Am J Hematol

.

2020

;

95

(

12

):

1511

-

1521

.

11.

Winters

AC

,

Gutman

JA

,

Purev

E

, et al.

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia

.

Blood Adv

.

2019

;

3

(

20

):

2911

-

2919

.

12.

Gershon

A

,

Ma

E

,

Xu

T

, et al.

Early real-world first-line treatment with venetoclax plus HMAs versus HMA monotherapy among patients with AML in a predominately US community setting

.

Clin Lymphoma Myeloma Leuk

.

2023

;

23

(

5

):

e222

-

e231

.

13.

Vachhani

P

,

Flahavan

EM

,

Xu

T

, et al.

Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US

.

Oncologist

.

2022

;

27

(

11

):

907

-

918

.

14.

Gangat

N

,

Johnson

I

,

McCullough

K

, et al.

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia

.

Haematologica

.

2022

;

107

(

10

):

2501

-

2505

.